135 related articles for article (PubMed ID: 1333894)
1. Approaches to optimal dosing of hexamethylene bisacetamide.
Conley BA; Egorin MJ; Sinibaldi V; Sewack G; Kloc C; Roberts L; Zuhowski EG; Forrest A; Van Echo DA
Cancer Chemother Pharmacol; 1992; 31(1):37-45. PubMed ID: 1333894
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
3. Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.
Rowinsky EK; Ettinger DS; McGuire WP; Noe DA; Grochow LB; Donehower RC
Cancer Res; 1987 Nov; 47(21):5788-95. PubMed ID: 3664482
[TBL] [Abstract][Full Text] [Related]
4. Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.
Rowinsky EK; Conley BA; Jones RJ; Spivak JL; Auerbach M; Donehower RC
Leukemia; 1992 Jun; 6(6):526-34. PubMed ID: 1602791
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
Conley BA; Forrest A; Egorin MJ; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1989 Jun; 49(12):3436-40. PubMed ID: 2720696
[TBL] [Abstract][Full Text] [Related]
6. Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.
Egorin MJ; Zuhowski EG; Cohen AS; Geelhaar LA; Callery PS; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6142-6. PubMed ID: 3664514
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer.
Rowinsky EK; Ettinger DS; Grochow LB; Brundrett RB; Cates AE; Donehower RC
J Clin Oncol; 1986 Dec; 4(12):1835-44. PubMed ID: 3783206
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
Young CW; Fanucchi MP; Declan Walsh T; Baltzer L; Yaldaei S; Stevens YW; Gordon C; Tong W; Rifkind RA; Marks PA
Cancer Res; 1988 Dec; 48(24 Pt 1):7304-9. PubMed ID: 3191501
[TBL] [Abstract][Full Text] [Related]
9. The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide.
Conley BA; Sewack GF; Egorin MJ; Subramanyam B; Page JG; Grieshaber CK
Cancer Chemother Pharmacol; 1991; 28(1):33-8. PubMed ID: 2040031
[TBL] [Abstract][Full Text] [Related]
10. Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusions.
Conley BA; Egorin MJ; Zuhowski EG; Sinibaldi VJ; Peterson DE
Cancer Chemother Pharmacol; 1988; 22(1):65-8. PubMed ID: 3396146
[TBL] [Abstract][Full Text] [Related]
11. Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.
Rowinsky EK; Donehower RC; Spivak JL; Burke PJ; Griffin CA; Jones RJ
J Natl Cancer Inst; 1990 Dec; 82(24):1926-31. PubMed ID: 2250314
[TBL] [Abstract][Full Text] [Related]
12. Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.
Ward FT; Kelley JA; Roth JS; Lombardo FA; Weiss RB; Leyland-Jones B; Chun HG
Cancer Res; 1991 Apr; 51(7):1803-10. PubMed ID: 2004365
[TBL] [Abstract][Full Text] [Related]
13. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.
Andreeff M; Stone R; Michaeli J; Young CW; Tong WP; Sogoloff H; Ervin T; Kufe D; Rifkind RA; Marks PA
Blood; 1992 Nov; 80(10):2604-9. PubMed ID: 1421378
[TBL] [Abstract][Full Text] [Related]
14. Induction of differentiation of human promyelocytic leukemia cells (HL60) by metabolites of hexamethylene bisacetamide.
Snyder SW; Egorin MJ; Geelhaar LA; Hamburger AW; Callery PS
Cancer Res; 1988 Jul; 48(13):3613-6. PubMed ID: 3163938
[TBL] [Abstract][Full Text] [Related]
15. Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA).
Conley BA; Callery PS; Egorin MJ; Subramanyam B; Geelhaar LA; Pan SS
Life Sci; 1988; 43(9):793-800. PubMed ID: 3137409
[TBL] [Abstract][Full Text] [Related]
16. Differentiating agent, hexamethylene bisacetamide, inhibits neointimal formation after vascular injury.
Ishikawa S; Hori S; Kusuhara M; Kanai Y; Handa S; Yamaguchi K; Hosoda Y; Ogawa S
Coron Artery Dis; 1997 Jan; 8(1):28-32. PubMed ID: 9101119
[TBL] [Abstract][Full Text] [Related]
17. Brain pH responses to sodium bicarbonate and Carbicarb during systemic acidosis.
Shapiro JI; Whalen M; Kucera R; Kindig N; Filley G; Chan L
Am J Physiol; 1989 May; 256(5 Pt 2):H1316-21. PubMed ID: 2541632
[TBL] [Abstract][Full Text] [Related]
18. Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells.
Li XN; Du ZW; Huang Q
J Neurosurg; 1996 May; 84(5):831-8. PubMed ID: 8622158
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
[TBL] [Abstract][Full Text] [Related]
20. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60.
Breitman TR; He RY
Cancer Res; 1990 Oct; 50(19):6268-73. PubMed ID: 2400989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
